[uam_ad id="317182"]

RIO DE JANEIRO, BRAZIL - Hyderabad-based Bharat Biotech this week offered Brazil a COVID-19 vaccine that is in late-stage clinical trials and a possible technology transfer partnership, a company executive said on Friday, November 20th.

The private pharmaceutical company based in the southern city of Hyderabad is developing a whole-virion inactivated vaccine called Covaxin that could be licensed by the second quarter of 2021.

“The data looks really good in terms of reduction and also prevention of disease, and we started our Phase 3 clinical trials this week,” Executive Director Sai Prasad told Reuters.

Bharat Biotech is . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?